Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned an average rating of “Moderate Buy” from the ten analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $15.7143.

ALT has been the topic of a number of analyst reports. Wall Street Zen raised Altimmune from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Citizens Jmp cut their target price on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Leerink Partners started coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 target price on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, June 24th.

Institutional Trading of Altimmune

A number of hedge funds have recently bought and sold shares of ALT. Vanguard Group Inc. raised its holdings in Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after acquiring an additional 1,206,514 shares during the last quarter. State Street Corp boosted its holdings in shares of Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after purchasing an additional 1,518,448 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Altimmune by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock worth $8,278,000 after purchasing an additional 275,025 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Altimmune by 140.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock valued at $4,871,000 after purchasing an additional 787,036 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Price Performance

ALT stock opened at $3.05 on Thursday. The stock’s 50 day moving average price is $2.90 and its 200 day moving average price is $3.45. The firm has a market cap of $593.13 million, a P/E ratio of -3.28 and a beta of 0.27. The company has a debt-to-equity ratio of 0.12, a quick ratio of 29.56 and a current ratio of 29.56. Altimmune has a 1 year low of $2.56 and a 1 year high of $6.44.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. On average, sell-side analysts expect that Altimmune will post -0.64 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.